Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 2  |  Page : 347-353

Clinical significance of adiponectin expression in colon cancer patients


1 Department of Medical Oncology, Faculty of Medicine, Firat University, Elazig, Turkey
2 Department of Medical Oncology, Faculties of Medicine, Uludag University, Bursa, Turkey
3 Department of Medical Pathology, Faculties of Medicine, Uludag University, Bursa, Turkey

Correspondence Address:
Mustafa Canhoroz
Department of Medical Oncology, Firat University Faculty of Medicine, Elazig, 23100
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.136634

Rights and Permissions

Purpose: Surgery is the definitive treatment for early colon cancers. Adjuvant therapies are used with the aim of eradicating micrometastases and improving cure rates. Recent studies have proposed that adiponectin might be responsible for obesity-related malignancies. We investigated the prognostic value of this cytokine. Materials and Methods: Patients who underwent surgical removal of stage II or III (TNM staging) primary tumors and were followed for at least three years were included in the study given adequate specimen for immunohistochemical evaluation. Based on these criteria, 53 patients were included. Results: Mean age was 58.3 ± 10.1 years (35-78 years). The mean follow-up time was 41 months (10-96 months). Immunohistochemical evaluation identified 21 patients (39.6%) with cytoplasmic adiponectin present in their specimens. The rates of recurrence were 42.9% (9/21) and 34.4% (11/32) in patients with and without adiponectin expression, respectively. In cases with adiponectin expression, mean disease - free survival was 60.3 ± 9.03 months, and in cases without adiponectin expression, mean disease - free survival was 68.7 ± 6.67 months (P = 0.414). Mean overall survival of patients with adiponectin expression was 65 months compared to 67 months for patients without (P = 0.786). Conclusion: Adiponectin, which is secreted by adipose tissue, may have a role in the development and progression of cancer via its pro-apoptotic and/or anti-proliferative effects. Adiponectin expression in tumor tissues is likely to have a negative effect on disease - free survival in patients with stage II/III colon cancer; however, no statistically significant effect was demonstrated.

Abstract in Chinese

脂联素表达水平在结肠癌患者的临床意义 摘要 目的:手术是治疗早期结肠癌的明确治疗手段。辅助疗法的目的是消除微转移和提高治愈率。最近的研究提出,脂联素可能与肥胖相关的恶性肿瘤有关。我们研究了这种细胞因子对预后价值。 材料和方法:收集整理53例手术切除的II期或III期(TNM分期)原发肿瘤患者,随访3年以上,每例病人包括了足够的标本供免疫组织化学评估。 结果:平均年龄为58.3±10.1岁(35~78岁)。平均随访时间为41个月(10~96个月)。免疫组化结果显示21例(39.6%)病人的标本存在胞浆脂联素表达。脂联素表达阳性和阴性的患者复发率分别为42.9%(9/21)和34.4%(11/32)。脂联素的表达阳性病例中,平均无病生存时间为为60.3±9.03个月,脂联素的表达阴性病例中,平均无病生存为68.7±6.67个月(P = 0.414)。有脂联素表达患者的平均总生存时间65个月,而无表达组为67个月(P = 0.786)。 结论:脂联素,它是由脂肪组织分泌的,可能在癌症的发生和发展中起作用,通过其促凋亡和/或抗增殖的影响。II / III期结肠癌患者中,脂联素高表达可能是结肠癌患者预后不良指标,但统计分析结果并不支持该结论。 关键词:脂联素,结肠癌,肥胖相关的恶性肿瘤



[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1661    
    Printed43    
    Emailed1    
    PDF Downloaded86    
    Comments [Add]    

Recommend this journal